On February 6, 2023 RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, reported that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2023 (Press release, RNAimmune, FEB 6, 2023, View Source [SID1234626897]). The AACR (Free AACR Whitepaper) Annual Meeting will take place April 14-19 in Orlando, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: A pan-ras mRNA vaccine elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer
Presenter: Dong Shen, MD PhD, RNAimmune founder and President
Session Category: Experimental and Molecular Therapeutics
Session Title: New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Session Date/Time: Tuesday, Apr 18, 2023, 2:30 PM – 4:30 PM ET
Note: The presentation will also be published in the online Proceedings of the AACR (Free AACR Whitepaper).
Venue: Orange County Convention Center, Orlando, Florida
RNAimmune will present a pre-clinical study showing the most recent mRNA cancer vaccine progress. The study shows immunization of the mRNA vaccine can elicit T and B cell responses, which are crucial in anti-cancer immunotherapy, and inhibit tumor growth in the mouse model of colon cancer, prolonging survival. Notably, the anti-tumor effect is further enhanced in the combination of anti-PD1 antibody.
RAS is one of the most common mutated oncogenes in human cancer. Unfortunately, there is still a lack of specifically effective medication for most RAS-mutated cancer patients. For G12C-mutated patients, drug resistance frequently appears soon after targeted therapy. The reported Pan RAS mRNA cancer vaccine was designed and screened by RNAimmune, which owns its proprietary independent intellectual property rights. Its anti-tumor effects have been validated both in vitro and in vivo. The current program yielded outstanding antitumor activity, and the Company plans to submit to the U.S. Food and Drug Administration an Investigational New Drug application after completion of the current dose titration study.
Found in 1907, AACR (Free AACR Whitepaper) is the first and largest cancer research organization dedicated to fighting against cancer. The annual meeting of AACR (Free AACR Whitepaper) is one of the biggest meetings in the global cancer research community, and it highlights the latest advances in anti-cancer research and development from all over the world.